Montelukast Sodium is a potent, selective, anti-inflammatory CysLT1 receptor antagonist (IC50 < 5nM) with no appreciable affect on the CysLT2 receptor. In rat colitis Montelukast Sodium has demonstrated the ability to increase PGE2 (Prostaglandin E2 - sc-201225) production and lower COX-2 expression. Inhibition is competitive with respect to leukotrienes - particularly LTD4, a biologically active mediator that plays an important role in the control of several biochemical pathways involving pulmonary and immune system function.
MONTELUKAST SODIUM
Structure
Product Description
Details |
|
|---|---|
Chemical Name |
MONTELUKAST SODIUM |
IUPAC Name |
sodium 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate |
CAS Number |
151767-02-1 |
Molecular Formula |
C35H35CINO3S.NA |
Synonyms |
mk-476;MK-476-d6;singulair;MONTELUKAST NA;MK-476, Singulair;Motelukast SodiuM;MONTELUKST SODIUM;MONTELUKAST SODIUM;Montelukast SoudiuM;Montelukast SodiuM USP |
Application |
A potent and highly selective CysLT1 receptor antagonist, without demonstrated CysLT2 activity |